TY - JOUR A1 - Wiegering, Armin A1 - Pfann, Christina A1 - Uthe, Friedrich Wilhelm A1 - Otto, Christoph A1 - Rycak, Lukas A1 - Mäder, Uwe A1 - Gasser, Martin A1 - Waaga-Gasser, Anna-Maria A1 - Eilers, Martin A1 - Germer, Christoph-Thomas T1 - CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression JF - PLoS ONE N2 - The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome. To determine whether CIP2A expression is elevated in colon cancer and whether it might serve as a prognostic marker for survival, we analysed CIP2A mRNA expression by real-time PCR in 104 colon cancer samples. CIP2A mRNA was overexpressed in colon cancer samples and CIP2A expression levels correlated significantly with tumour stage. We found that CIP2A serves as an independent prognostic marker for disease-free and overall survival. Further, we investigated CIP2A-dependent effects on levels of c-Myc, Akt and on cell proliferation in three colon cancer cell lines by silencing CIP2A using small interfering (si) and short hairpin (sh) RNAs. Depletion of CIP2A substantially inhibited growth of colon cell lines and reduced c-Myc levels without affecting expression or function of the upstream regulatory kinase, Akt. Expression of CIP2A was found to be dependent on MAPK activity, linking elevated c-Myc expression to deregulated signal transduction in colon cancer. KW - caco-2 cells KW - carcinomas KW - colon KW - colorectal cancer KW - MAPK signaling cascades KW - metastasis KW - protein expression KW - small interferring RNA Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97252 ER - TY - THES A1 - Wagner, Frank Wilhelm T1 - Literaturübersicht über Ergebnisse der Therapien von Oropharynxkarzinomen T1 - Literary overview of treatment results of oropharynx carcinomas N2 - Es wurde eine Literaturübersicht der Jahre 1966 bis 1996 über Therapieergeb-nisse von Plattenepithelkarzinomen des Oropharynx erstellt. Als Endergebnis wurde die 5-Jahres-Überlebenszeit festgelegt. Die Hauptlokalisationen für Oropharynxtumoren sind mit absteigender Häufigkeit die Tonsillenregion, der Zungengrund, der weiche Gaumen mit Uvula und die Pharynxwand. Die Behandlungsregime umfassten die alleinige Operation, die alleinige externe Strahlentherapie mit oder ohne interstitieller Bestrahlung, die Kombinations-therapie aus Operation und Radiotherapie sowie die kombinierte Behandlung aus Chemotherapie und Bestrahlung mit oder ohne Operation. Über die alleinige Radiotherapie fanden sich die meisten Publikationen, gefolgt von Veröffent-lichungen über die chirurgisch-radiologische Kombinationstherapie. Über die kombinierte Behandlung aus Chemotherapie und Bestrahlung mit oder ohne Ope-ration gab es die geringste Anzahl verwertbarer Veröffentlichungen. Beim Vergleich der verschiedenen Behandlungsarten lieferte die Operation mit nachfolgender Bestrahlung (OP+post-op.RT), die externe Bestrahlung plus interstitieller Radiotherapie (RT+iRT) und die alleinige Operation (all. OP) die besten Gesamtüberlebenszeiten, in denen die Verteilung der Tumorstadien nicht berücksichtigt wurden, für das Oropharynxkarzinom in den 90er Jahren. Für Patientenkollektive mit überwiegend frühen Tumorstadien zeigte die alleinige Operation (all. OP) die deutlichste Verbesserung der Überlebens-zeiten über den Beobachtungszeitraum und die besten Überlebenszeiten in den 90er Jahren, gefolgt von der externen Bestrahlung plus interstitieller Radio-therapie (RT+iRT). Die Kombinationstherapie aus Operation und Bestrahlung (OP&RT) wurde für diese Patientenkollektive nur ausnahmsweise angewendet. Für Patientenkollektive mit überwiegend fortgeschrittenen Tumorstadien liefer-te die Operation mit nachfolgender Bestrahlung (OP+post-op. RT) und die externe Bestrahlung plus interstitieller Radiotherapie (RT+iRT) die besten Überlebenszeiten in den 90er Jahren, wobei es für erstere eine größere Studienanzahl und eine deutlichere Tendenz zu verbesserten Überlebenszeiten über den Beobachtungszeitraum gab. Die kombinierte Behandlung aus Chemo-therapie und Radiotherapie (CT&RT) zeigte in den 90er Jahren deutlich schlechtere Überlebenszeiten. Für Tonsillen- und Zungengrundkarzinomen lieferte die Kombinationstherapie aus Operation und Bestrahlung (OP&RT) die besten Überlebenszeiten in den 90er Jahren sowohl für das Gesamtkollektiv als auch für die überwiegend fortge-schrittenen Tumorstadien, gefolgt von der externen Bestrahlung mit oder ohne interstitieller Radiotherapie (RT+iRT). N2 - A literary overview of treatment results of squamous cell carcinomas of the oropharynx between 1966 and 1996 was done. The final result was the 5-year-survival rate. The tonsillar region is the most common location of oropharyngeal carcinomas, followed by the base of tongue, the soft palate with uvula and the oro-pharyngeal wall. The treatment regimes were surgery alone, irradiation alone with or without interstitial radiotherapy, the combined therapy of surgery and irradiation and the combination of irradiation and chemotherapy with or without surgery. The most publications found were about radiotherapy alone, followed by publi-cations about the combined therapy of irradiation and surgery. The least publications found were about the combination of irradiation and chemotherapy with or without surgery. The different treatment regimes have been compared. Surgery with post-operative irradiation, radiotherapy with interstitial irra-diation and surgery alone resulted in the best survival rates in the 90’s for oropharyngeal carcinomas not considering the tumour stages. For patients with predominantly early stage oropharyngeal carcinomas surgery alone resulted in the clearest improvement of survival rates over the period of observation and the best survival rates in the 90’s, followed by external irradiation with intertitial radiotherapy. The combined therapy of surgery and irradiaton was applied to this group of patients in exception only. For patients with predominantly advanced oropharyngeal carcinomas the combi-nation of surgery and post-operative radiotherapy and external irradiation with interstitial radiotherapy resulted in the best survival rates in the 90’s. For surgery and post-operative radiotherapy there was a higher number of publications and a clearer tendency towards improved survival rates over the period of observation. The combination of irradiation and chemotherapy clearly resulted in poorer survival rates in the 90’s. The combination therapy of surgery and irradiation resulted in the best sur-vival rates in the 90’s for carcinomas of the tonsil and base of tongue for the total collective as well as for the group with predominantly advanced carcinomas. The external irradiation with interstitial radiotherapy was the second best treatment modality for these tumour locations. KW - Oropharynx KW - Karzinom KW - Plattenepithelkarzinom KW - Überlebenszeit KW - oropharynx KW - carcinomas KW - squamous cell carcinomas KW - survival Y1 - 2005 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-22615 ER - TY - JOUR A1 - Sbiera, Silviu A1 - Ronchi, Cristina L. A1 - Leich, Ellen A1 - Henzel, Katharina A1 - Rosenwald, Andreas A1 - Allolio, Bruno A1 - Fassnacht, Martin T1 - Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence? JF - PLoS ONE N2 - Adrenocortical tumors consist of benign adenomas and highly malignant carcinomas with a still incompletely understood pathogenesis. A total of 46 adrenocortical tumors (24 adenomas and 22 carcinomas) were investigated aiming to identify novel genes involved in adrenocortical tumorigenesis. High-resolution single nucleotide polymorphism arrays (Affymetrix) were used to detect copy number alterations (CNAs) and copy neutral losses of heterozygosity (cnLOH). Genomic clustering showed good separation between adenomas and carcinomas, with best partition including only chromosome 5, which was highly amplified in 17/22 malignant tumors. The malignant tumors had more relevant genomic aberrations than benign tumors, such as a higher median number of recurrent CNA (2631 vs 94), CNAs >100 Kb (62.5 vs 7) and CN losses (72.5 vs 5.5), and a higher percentage of samples with cnLOH (91% vs 29%). Within the carcinoma cohort, a precise genetic pattern (i.e. large gains at chr 5, 7, 12, and 19, and losses at chr 1, 2, 13, 17, and 22) was associated with a better prognosis (overall survival: 72.2 vs 35.4 months, P=0.063). Interestingly, >70% of gains frequent in beningn were also present in malignant tumors. Notch signaling was the most frequently involved pathway in both tumor entities. Finally, a CN gain at imprinted “IGF2” locus chr 11p15.5 appeared to be an early alteration in a multi-step tumor progression, followed by the loss of one or two alleles, associated with increased IGF2 expression, only in carcinomas. Our study serves as database for the identification of genes and pathways, such as Notch signaling, which could be involved in the pathogenesis of adrenocortical tumors. Using these data, we postulate an adenoma-carcinoma sequence for these tumors. KW - adenomas KW - cancer diagnosis KW - cancer detection KW - carcinogenesis KW - carcinomas KW - chromosomes KW - genetic loci KW - malignant tumors KW - notch signaling Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97218 ER - TY - JOUR A1 - Ronchi, Cristina L. A1 - Sbiera, Silviu A1 - Volante, Marco A1 - Steinhauer, Sonja A1 - Scott-Wild, Vanessa A1 - Altieri, Barbara A1 - Kroiss, Matthias A1 - Bala, Margarita A1 - Papotti, Mauro A1 - Deutschbein, Timo A1 - Terzolo, Massimo A1 - Fassnacht, Martin A1 - Allolio, Bruno T1 - CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma N2 - Background Adrenocortical tumors comprise frequent adenomas (ACA) and rare carcinomas (ACC). Human cytochrome P450 2W1 (CYP2W1) is highly expressed in some cancers holding the potential to activate certain drugs into tumor cytotoxins. Objective To investigate the CYP2W1 expression in adrenal samples and its relationship with clinical outcome in ACC. Material and Methods CYP2W1 expression was investigated by qRT-PCR in 13 normal adrenal glands, 32 ACA, 25 ACC, and 9 different non-adrenal normal tissue samples and by immunohistochemistry in 352 specimens (23 normal adrenal glands, 33 ACA, 239 ACC, 67 non-adrenal normal or neoplastic samples). Results CYP2W1 mRNA expression was absent/low in normal non-adrenal tissues, but high in normal and neoplastic adrenal glands (all P<0.01 vs non-adrenal normal tissues). Accordingly, CYP2W1 immunoreactivity was absent/low (H-score 0–1) in 72% of non-adrenal normal tissues, but high (H-score 2–3) in 44% of non-adrenal cancers, in 65% of normal adrenal glands, in 62% of ACAs and in 50% of ACCs (all P<0.001 vs non-adrenal normal tissues), being significantly increased in steroid-secreting compared to non-secreting tumors. In ACC patients treated with mitotane only, high CYP2W1 immunoreactivity adjusted for ENSAT stage was associated with longer overall survival and time to progression (P<0.05 and P<0.01, respectively), and with a better response to therapy both as palliative (response/stable disease in 42% vs 6%, P<0.01) or adjuvant option (absence of disease recurrence in 69% vs 45%, P<0.01). Conclusion CYP2W1 is highly expressed in both normal and neoplastic adrenal glands making it a promising tool for targeted therapy in ACC. Furthermore, CYP2W1 may represent a new predictive marker for the response to mitotane treatment. KW - CYP2W1 KW - cancer treatment KW - adrenal glands KW - carcinomas KW - drug therapy KW - hormones KW - immune response KW - immunohistochemistry techniques KW - surgical oncology Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-113096 ER - TY - JOUR A1 - Adelfinger, Marion A1 - Gentschev, Ivaylo A1 - de Guibert, Julio Grimm A1 - Weibel, Stephanie A1 - Langbein-Laugwitz, Johanna A1 - Härtl, Barbara A1 - Escobar, Hugo Murua A1 - Nolte, Ingo A1 - Chen, Nanhai G. A1 - Aguilar, Richard J. A1 - Yu, Yong A. A1 - Zhang, Qian A1 - Frentzen, Alexa A1 - Szalay, Aladar A. T1 - Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy JF - PLoS ONE N2 - Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis. In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model. KW - antibodies KW - cancer treatment KW - carcinomas KW - vaccinia virus KW - oncolytic viruses KW - viral replication KW - cell cultures KW - enzyme-linked immunoassays Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119387 VL - 9 IS - 8 ER -